Clinical Trial Update: Study of EYP-1901 in Patients With Nonproliferative Diabetic Retinopathy (NPDR) [Phase 2]

View source ↗

Summary

Phase 2 study of EYP-1901 for nonproliferative diabetic retinopathy has completed. Results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nonproliferative Diabetic Retinopathy

Drugs mentioned

• EYP-1901

Snippet

Sponsor: EyePoint Pharmaceuticals, Inc. | Conditions: Nonproliferative Diabetic Retinopathy | Phase 2 | Status: COMPLETED | Results posted: 2025-07-28